<DOC>
	<DOC>NCT01677390</DOC>
	<brief_summary>This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.</brief_summary>
	<brief_title>A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Diagnosis of metastatic renal cell carcinoma with confirmed CD70 expression Previously treated with at least 1 tyrosine kinase inhibitor (TKI) Measurable disease Eastern Cooperative Oncology Group performance status 0 or 1 Adequate lung and renal function Prior treatment with antiCD70directed therapy Received more than one prior treatment with an mTOR inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>monomethylauristatin F</keyword>
	<keyword>Carcinoma, Renal Cell</keyword>
	<keyword>Antigens, CD70</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>